US5402777A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and devices for facilitated non-invasive oxygen monitoring
Assignee: Alza Corp
•
Filing: 1992-06-03
•
Granted: 1995-04-04
•
Expires: 2012-06-03
Abstract
Abstract The present invention is directed to a sensor system for use with a blood characteristic measurement device such as a pulse oximeter, on areas of the body having low normal cutaneous blood flow and for monitoring a blood characteristic such as oxygen saturation and pulse rate of patients, preferably over an extended period of time. The sensor system includes (a) a transdermal device containing a blood perfusion-enhancing agent that is administered in a controlled amount to the skin of a human patient and (b) a skin surface sensor.
Inventors
- 👤 Jessica A. Warring
- 👤 David B. Swedlow
- 👤 Michael J. N. Cormier
- 👤 Su Il Yum
- 👤 Lina T. Taskovich
- 👤 Albert Ollerdessen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 06:01
CPC Classifications
A; A61; A61B; A61B5/00; A61B5/68; A61B5/6801; A61B5/683; A61B5/6832; A61B5/6833; A61B5/02; A61B5/024; A61B5/02416; A61B5/02427; A61B5/02433; A61B5/145; A61B5/1455; A61B5/14551; A61B5/14552
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
81 words
A transdermal delivery device for facilitating the non-invasive monitoring of a characteristic of a patient's blood vessels, wherein the device consists essentially of: (a) a backing member that is substantially impermeable to a perfusion-enhancing agent; (b) a first adhesive layer adjacent to the skin-distal surface of the backing member; (c) perfusion agent reservoir means adjacent to the skin-proximal surface of the backing member; and (d) means for maintaining said reservoir in perfusion agent transmitting relationship to the skin of the patient.
Claim 2
Dependent Claim
81 words
A transdermal delivery device for facilitating the non-invasive monitoring of a characteristic of a patient's blood vessels, wherein the device consists essentially of: (a) a backing member that is substantially impermeable to a perfusion-enhancing agent; (b) a first adhesive layer adjacent to the skin-distal surface of the backing member; (c) perfusion agent reservoir means adjacent to the skin-proximal surface of the backing member; and (d) means for maintaining said reservoir in perfusion agent transmitting relationship to the skin of the patient.
Claim 3
Dependent Claim
15 words
A device according to claim 1 wherein said maintaining means comprises a second adhesive layer.
Claim 4
Dependent Claim
11 words
A device according to claim 1 wherein the device is opaque.
Claim 5
Dependent Claim
13 words
A device according to claim 1 wherein the perfusion-enhancing agent is a vasodilator.
Claim 6
Dependent Claim
21 words
A device according to claim 4 wherein the vasodilator is selected from nicotinic acid and lower alkyl esters of nicotinic acid.
Claim 7
Dependent Claim
13 words
A device according to claim 1 wherein the perfusion-enhancing agent is methyl nicotinate.
Claim 8
Dependent Claim
18 words
A device according to claim 1 wherein the device further comprises an emitter window and a detector window.
Claim 9
Dependent Claim
38 words
A device according to claim 1 wherein the perfusion-enhancing agent is methyl nicotinate, and the device further comprises a second adhesive layer adjacent to the skin-proximal surface of the rate-controlling membrane, an emitter window and a detector window.
Claim 10
Dependent Claim
13 words
A device according to claim 1 wherein the perfusion-enhancing agent is a counterirritant.
Claim 11
Dependent Claim
25 words
A device according to claim 1 wherein said device further comprises a rate controlling membrane adjacent to the skin proximal surface of said reservoir means.
Claim 12
Dependent Claim
98 words
A transdermal delivery device for delivering a perfusion-enhancing agent to a human at a substantially constant rate over an extended period of time to obtain a localized increase of the cutaneous blood flow, wherein the device consists essentially of: (a) a backing member that is substantially impermeable to a perfusion-enhancing agent; (b) a first adhesive layer adjacent to the skin-distal surface of the backing member; (c) a perfusion agent reservoir means adjacent to the skin-proximal surface of the backing member; and (d) means for maintaining said reservoir in perfusion agent transmitting relationship to the skin of the patient.
Claim 13
Dependent Claim
98 words
A transdermal delivery device for delivering a perfusion-enhancing agent to a human at a substantially constant rate over an extended period of time to obtain a localized increase of the cutaneous blood flow, wherein the device consists essentially of: (a) a backing member that is substantially impermeable to a perfusion-enhancing agent; (b) a first adhesive layer adjacent to the skin-distal surface of the backing member; (c) a perfusion agent reservoir means adjacent to the skin-proximal surface of the backing member; and (d) means for maintaining said reservoir in perfusion agent transmitting relationship to the skin of the patient.
Claim 14
Dependent Claim
16 words
A device according to claim 11 which further comprises an emitter window and a detector window.
Claim 15
Dependent Claim
15 words
A device according to claim 11 wherein said maintaining means comprises a second adhesive layer.
Claim 16
Dependent Claim
11 words
A device according to claim 11 wherein the device is opaque.
Claim 17
Dependent Claim
13 words
A device according to claim 11 wherein the perfusion-enhancing agent is a vasodilator.
Claim 18
Dependent Claim
21 words
A device according to claim 15 wherein the vasodilator is selected from nicotinic acid and lower alkyl esters of nicotinic acid.
Claim 19
Dependent Claim
13 words
A device according to claim 11 wherein the perfusion-enhancing agent is methyl nicotinate.
Claim 20
Dependent Claim
38 words
A device according to claim 11 wherein the perfusion-enhancing agent is methyl nicotinate, and the device further comprises a second adhesive layer adjacent to the skin-proximal surface of the rate-controlling membrane, an emitter window and a detector window.
Claim 21
Dependent Claim
13 words
A device according to claim 11 wherein the perfusion-enhancing agent is a counterirritant.
Claim 22
Dependent Claim
19 words
A device according to claim 11 wherein the extended period of time is from 8 hours to 3 days.
Claim 23
Dependent Claim
25 words
A device according to claim 11 wherein said device further comprises a rate controlling membrane adjacent to the skin proximal surface of said reservoir means.
References Cited (Backward Citations)
US3598122A
Cited
US3598123A
Cited
US3993073A
Cited
US3598122B1
Cited
US3628525A
Cited
USRE31440E
Cited
US3742951A
Cited
US3742951B1
Cited
US4144317A
Cited
US4031894A
Cited
US4060084A
Cited
US4296752A
Cited
US4201211A
Cited
US4324256A
Cited
US4379454A
Cited
US4849226A
Cited
US4661105A
Cited
US4725272A
Cited
US4517982A
Cited
US4534356A
Cited
US4653498B1
Cited
US4653498A
Cited
US4536274A
Cited
US4830014A
Cited
US4747845A
Cited
US4488557A
Cited
US4687481A
Cited
US4847260A
Cited
US4764382A
Cited
US4692462A
Cited
US4685464A
Cited
US4926867A
Cited
US4908027A
Cited
US4943435A
Cited
US5007423A
Cited
US5267563A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-04-03 | 1998-10-03 | 1999-04-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-04-03 | 2002-10-03 | 2003-04-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-04-03 | 2006-10-03 | 2007-04-04 | $7700.00 | Window Closed / Lapsed |